Brokerages Set ICON Public Limited (NASDAQ:ICLR) PT at $289.10

Shares of ICON Public Limited (NASDAQ:ICLR) have earned an average rating of “Moderate Buy” from the fifteen brokerages that are presently covering the firm, MarketBeat reports. Three equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company. The average 1-year price target among analysts that have covered the stock in the last year is $287.00.

ICLR has been the subject of several recent research reports. Citigroup reduced their price target on shares of ICON Public from $300.00 to $290.00 and set a “buy” rating for the company in a report on Monday. Royal Bank of Canada initiated coverage on shares of ICON Public in a research note on Tuesday. They issued an “outperform” rating and a $263.00 price objective for the company. TD Cowen dropped their target price on ICON Public from $369.00 to $285.00 and set a “buy” rating on the stock in a research report on Friday, October 25th. Robert W. Baird reduced their price target on ICON Public from $249.00 to $225.00 and set a “neutral” rating for the company in a research report on Wednesday, November 20th. Finally, The Goldman Sachs Group dropped their price objective on ICON Public from $370.00 to $280.00 and set a “buy” rating on the stock in a research report on Friday, October 25th.

ICON Public Stock Down 1.5 %

Shares of NASDAQ ICLR opened at $219.34 on Thursday. The stock has a 50 day moving average price of $211.42 and a 200 day moving average price of $273.13. The firm has a market capitalization of $18.09 billion, a price-to-earnings ratio of 24.45, a PEG ratio of 1.54 and a beta of 1.20. ICON Public has a 52-week low of $183.38 and a 52-week high of $347.72. The company has a debt-to-equity ratio of 0.35, a quick ratio of 1.34 and a current ratio of 1.34.

ICON Public (NASDAQ:ICLR) last posted its quarterly earnings results on Wednesday, October 23rd. The medical research company reported $3.35 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.72 by ($0.37). The firm had revenue of $2.03 billion for the quarter, compared to the consensus estimate of $2.13 billion. ICON Public had a return on equity of 11.91% and a net margin of 9.00%. ICON Public’s quarterly revenue was down 1.2% compared to the same quarter last year. During the same period in the previous year, the company posted $3.10 EPS. Sell-side analysts expect that ICON Public will post 13.42 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. GAMMA Investing LLC lifted its stake in shares of ICON Public by 64.0% during the fourth quarter. GAMMA Investing LLC now owns 433 shares of the medical research company’s stock worth $91,000 after buying an additional 169 shares during the period. Foyston Gordon & Payne Inc acquired a new position in shares of ICON Public in the 3rd quarter valued at $11,672,000. Icon Wealth Advisors LLC raised its stake in ICON Public by 861.1% in the 3rd quarter. Icon Wealth Advisors LLC now owns 13,215 shares of the medical research company’s stock worth $3,797,000 after acquiring an additional 11,840 shares during the last quarter. First Horizon Advisors Inc. lifted its position in ICON Public by 33.9% during the 3rd quarter. First Horizon Advisors Inc. now owns 597 shares of the medical research company’s stock worth $172,000 after acquiring an additional 151 shares during the period. Finally, Arkadios Wealth Advisors grew its stake in ICON Public by 5.0% during the 3rd quarter. Arkadios Wealth Advisors now owns 1,293 shares of the medical research company’s stock valued at $371,000 after purchasing an additional 62 shares during the last quarter. Institutional investors and hedge funds own 95.61% of the company’s stock.

ICON Public Company Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.